Clinuvel Provides EPP Therapy Scenesse To Chinese Patients
Move Is Part Of Asian Entry Strategy
Individual patients in China will soon be able to gain access to Scenesse, a groundbreaking therapy for the rare phototoxicity disorder, erythropoietic protoporphyria, under a named patient program, pending the submission of a formal approval application. The product’s developer, Clinuvel, says it is currently awaiting a response on its filing with the Australian regulator and that it has other markets such as Japan in its sights.
You may also be interested in...
First-in-class drug for rare disease EPP obtains FDA approval, company plans treatment center-based rollout. Scenesse, on the market in Europe since 2016, has faced reimbursement hurdles.
An appeals panel has upheld some of the objections to NICE’s decision not to recommend Clinuvel’s Scenesse for NHS funding in England. The HTA body’s Highly Specialized Technologies committee will now have to reconsider its guidance in light of the panel’s conclusions.
The UK government says it is on track to vaccinate the 15 million most vulnerable people by mid-February, and that a “major study” is under way to assess the potential impact of the new UK variant on vaccine efficacy.